Mary J. Bossard, Madison, AL (US); Cherie F. Ali, Burlingame, CA (US); Xiaofeng Liu, Belmont, CA (US); Deborah H. Charych, Albany, CA (US); and Yujun Wang, Fremont, CA (US)
Assigned to Nektar Therapeutics, San Francisco, CA (US)
Filed by Nektar Therapeutics, San Francisco, CA (US)
Filed on Jul. 12, 2021, as Appl. No. 17/373,665.
Application 16/139,957 is a division of application No. 15/835,125, filed on Dec. 7, 2017, granted, now 10,960,079, issued on Mar. 30, 2021.
Application 15/835,125 is a division of application No. 13/884,901, granted, now 9,861,705, issued on Jan. 9, 2018, previously published as PCT/US2011/060408, filed on Nov. 11, 2011.
Application 17/373,665 is a continuation of application No. 16/139,957, filed on Sep. 24, 2018, granted, now 11,091,525.
Claims priority of provisional application 61/413,236, filed on Nov. 12, 2010.
Prior Publication US 2021/0340210 A1, Nov. 4, 2021
1. A composition comprising a conjugate of an interleukin-2 (IL-2) moiety, the conjugate comprising from three to seven branched poly(ethylene glycol) polymers, each covalently attached via a releasable linkage to an amino group of the IL-2 moiety, wherein the IL-2 moiety is aldesleukin, each branched poly(ethylene glycol) has a weight average molecular weight from about 20,000 daltons to about 85,000 daltons, and the composition possesses no IL-2 activity prior to in vivo release of the branched poly(ethylene glycol) polymer(s) from the conjugate.
